Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

Original reporting
Published Nov 18, 2026, 2:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 8:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The approval expands the drug's addressable market and could boost Novartis' specialty drug revenue, while also prompting insurers to negotiate pricing under Medicare's upcoming negotiations.

02

Market read

First FDA approval for an IL‑17 therapy in PMR, offering a new revenue stream and potential stock catalyst for Novartis.

03

What to watch

Potential safety concerns (serious infections) and competition from existing IL‑6 blocker Kevzara could temper demand.

Relevance 7/10Novelty 9/10Timing: today

Background

Cosentyx is already approved for psoriasis, psoriatic arthritis and other indications; this is its 11th U.S. indication.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

FDA approved Novartis' Cosentyx (secukinumab) 150 mg for polymyalgia rheumatica, based on REPLENISH trial data.

Expected impact

likely upward pressure as investors price in additional revenue from PMR indication

Evidence & confidence

First FDA approval for an IL‑17 blocker in PMR, doubling sustained remission versus placebo, adds a sizable new market to an already high‑priced specialty drug.

Market effects

Biotech sector may benefit from renewed interest in IL‑17 therapies and specialty drug pipelines.

U.S. specialty pharma stocks could see modest gains; European peers may feel competitive pressure.

Adds to global pipeline of biologics for inflammatory diseases, potentially influencing worldwide market sentiment on biotech approvals.

Counterpoint

High cost and modest remission rates may limit uptake; insurers could push back on pricing.

Key entities

  • Novartis

    Pharmaceutical company receiving FDA approval for Cosentyx in PMR.

  • Cosentyx (secukinumab)

    IL‑17A blocking biologic now approved for polymyalgia rheumatica.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.